Lanreotide inhibits human jejunal secretion induced by prostaglandin E1 in healthy volunteers.
1. Somatostatin inhibits hormonal secretions in the gastrointestinal tract. Somatostatin analogues are used in the treatment of VIPome-related watery diarrhoea. In addition, more than 10% of patients with AIDS suffer from diarrhoea likely due to the increased intestinal secretion of water and ions. However, the direct effect of somatostatin on the flux of water and ions in the intestine has not been, so far, analyzed in vivo. The aim of the present study was to evaluate the effect of lanreotide, a somatostatin analogue, on the movements of water and ions in the jejunum in man. 2. Accordingly, 10 healthy volunteers (age 18-35 years, mean 27) and two patients with AIDS (26 and 33 years) suffering from water diarrhoea (> 800 ml day-1) underwent intestinal perfusion using a four lumen tube with proximal occluding balloon. The segment tested was 25 cm long. The jejunum was infused by an isotonic control saline solution containing polyethylene glycol (PEG) as nonabsorbable marker. Basal jejunal secretions were measured in all subjects. Prostaglandin E1 (PGE1) was administered intraluminally to stimulate jejunal secretion in healthy volunteers. The effect of intravenous lanreotide on the jejunal PGE1-induced secretions of water and electrolytes was analysed in healthy subjects and on the basal secretions in AIDS patients. Each period was analyzed on the basis of three (10 min) successive intestinal juice collections after 20-30 min equilibration time. The antisecretory effect of lanreotide was evaluated in each subject as the difference between fluxes compared to the control period. 3. In healthy volunteers, PGE1 induced secretion of H2O, Na+, K+ and Cl- in the jejunum and lanreotide reduced significantly PGE1-induced response. In both AIDS patients basal fluxes of water and ions were reduced by lanreotide in a dose-dependent manner. 4. Somatostatin can reduce stimulated-jejunal secretion of ions and water in normal subjects and may improve water diarrhoea in AIDS patients.
Sobhani
I
I
Service d'Hépato-Gastro-Entérologie, Hôpital Bichat, Paris, France.
René
E
E
Ramdani
A
A
Bayod
F
F
Sabbagh
L C
LC
Thomas
F
F
Mignon
M
M
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000378:metabolism*; D000293:Adolescent; D000328:Adult; D000527:Alprostadil / Q000494:pharmacology*; D003967:Diarrhea / Q000150:complications; D004573:Electrolytes / Q000378:metabolism; D006801:Humans; D017136:Ion Transport; D007583:Jejunum / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D010456:Peptides, Cyclic / Q000494:pharmacology*; D012016:Reference Values; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000494:pharmacology; D014867:Water / Q000378:metabolism
D004573:Electrolytes; D010456:Peptides, Cyclic; D014867:Water; C060347:lanreotide; D013004:Somatostatin; D000527:Alprostadil